| 吴 颖,魏 敏,刘 洪,冀瑞晴,王思梦.宫颈癌组织LRP11、SOX12表达与临床病理特征以及预后的关系研究[J].,2023,(17):3326-3330 |
| 宫颈癌组织LRP11、SOX12表达与临床病理特征以及预后的关系研究 |
| Study on the Relationship between the Expressions of LRP11, SOX12 and Clinicopathologic Characteristics and Prognosis in Cervical Cancer Tissue |
| 投稿时间：2023-02-28 修订日期：2023-03-23 |
| DOI：10.13241/j.cnki.pmb.2023.17.024 |
| 中文关键词: 宫颈癌 LRP11 SOX12 临床病理特征 预后 |
| 英文关键词: Cervical cancer LRP11 SOX12 Clinicopathological characteristics Prognosis |
| 基金项目:江苏省妇幼健康科研项目（F201666） |
|
| 摘要点击次数: 312 |
| 全文下载次数: 180 |
| 中文摘要: |
| 摘要 目的：探讨宫颈癌组织中低密度脂蛋白受体相关蛋白11（LRP11）、性别决定区域Y-BOX12（SOX12）表达特点，分析其与临床病理特征以及预后的关系。方法：选择2015年7月至2017年10月徐州医科大学附属医院收治的90例宫颈癌患者，取其手术切除的宫颈癌组织和癌旁正常组织，采用免疫组化法检测LRP11、SOX12阳性表达率。比较不同临床病理特征宫颈癌组织中LRP11、SOX12表达差异。术后随访至2022年10月，Kaplan-Meier生存曲线分析不同LRP11、SOX12表达水平宫颈癌患者无进展生存期（PFS）和总生存期（OS）差异。结果：宫颈癌组织中LRP11、SOX12阳性表达率高于癌旁组织（P＜0.05）。低度分化、FIGO分期II期、盆腔淋巴结转移宫颈癌患者癌组织中LRP11、SOX12阳性表达率高于中高度分化、FIGO分期I期、无盆腔淋巴结转移宫颈癌患者（P＜0.05）。中位随访时间35（15-45）个月。共4例失访，成功随访病例为86例。LRP11、SOX12阳性表达宫颈癌患者的5年PFS生存率分别为67.19%，63.79%，明显低于LRP11、SOX12阴性表达宫颈癌患者的86.36%、89.29%（P＜0.05）。LRP11、SOX12阳性表达宫颈癌患者的5年OS生存率分别为85.94%、84.48%，而LRP11、SOX12阴性表达宫颈癌患者的5年OS生存率均为100%（P＞0.05）。结论：宫颈癌组织中LRP11、SOX12阳性表达率显著增高，与宫颈癌恶性临床病理特征以及低PFS生存率有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression characteristics of low-density lipoprotein receptor-related protein 11 (LRP11) and sex determining region Y-BOX12 (SOX12) in cervical cancer tissue, and to analyze their relationship with clinicopathological characteristics and prognosis. Methods: 90 patients with cervical cancer who were admitted to the Affiliated Hospital of Xuzhou Medical University from July 2015 to October 2017 were selected. The surgically removed cervical cancer tissue and normal paracancer tissue were collected, and the positive expression rates of LRP11 and SOX12 were detected by immunohistochemical method. The expression difference of LRP11 and SOX12 in cervical cancer tissue with different clinicopathological characteristics were compared. Postoperative follow-up was conducted until October 2022, Kaplan-Meier survival curve was used to analyze the differences in progression-free survival (PFS) and overall survival (OS) of patients with cervical cancer with different LRP11 and SOX12 expression levels. Results: The positive expression rates of LRP11 and SOX12 in cervical cancer tissue were higher than those in paracancer tissue(P＜0.05). The positive expression rates of LRP11 and SOX12 in cancer tissue of patients with low differentiation, FIGO stage II stage and pelvic lymph node metastasis were higher than those of patients with moderate and highly differentiation, FIGO stage I stage and no pelvic lymph node metastasis(P＜0.05). At a median follow-up of 35(15-45) months. A total of 4 cases were lost and 86 cases were successfully followed-up. The 5-year PFS survival rates of patients with cervical cancer with LRP11 and SOX12 positive expression were 67.19% and 63.79%, respectively, significantly lower than 86.36% and 89.29% of patients with cervical cancer with LRP11 and SOX12 negative expression(P＜0.05). The 5-year OS survival rates of patients with cervical cancer with LRP11 and SOX12 positive expression were 85.94% and 84.48%, while the 5-year OS survival rates of patients with cervical cancer with LRP11 and SOX12 negative expression were 100%(P＞0.05). Conclusion: The positive expression rate of LRP11 and SOX12 in cervical cancer tissue significantly increased, which are related to malignant clinicopathological characteristics of cervical cancer and low survival rate of PFS. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
